Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942354 | 1.00 | CTSL (0.58) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL5149531 | 0.97 | GAA (0.61) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL5148495 | 0.92 | CTSL (0.61) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL941250 | 0.92 | CTSL (0.61) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL27649749 | 0.86 | GAA (0.60) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL15474382 | 0.81 | MAPT (0.49) | GAAMAPTL3MBTL1 | |
| SCHEMBL941477 | 0.81 | CTSL (0.66) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL941478 | 0.81 | CTSL (0.66) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL27627082 | 0.80 | CTSL (0.64) | CTSLGAAMAPTL3MBTL1ATM | |
| SCHEMBL8096310 | 0.80 | CTSL (0.57) | CTSLGAAMAPTL3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276017-A1 | Thiadiazoline Derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1632484-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276017-A1 | Thiadiazoline Derivative | BRD7, NR3C2, NR5A2 | CTSL 4567/4885GAA 4855/4885MAPT 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.